Fosmanogepix is under clinical development by Basilea Pharmaceutica and currently in Phase II for Candidiasis. According to GlobalData, Phase II drugs for Candidiasis have a 64% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Fosmanogepix’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Recommended Buyer's Guides
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Fosmanogepix overview
APX-001 is under development for the treatment of candidiasis and invasive aspergillosis. The drug candidate is administered through the intravenous and oral route. The drug candidate targets GWT1 and is developed based on a platform approach to improving small molecule drugs by the addition of a second small molecule to an existing drug.
It was under development for the treatment for cryptococcosis, coccidioidomycosis, scedosporiosis, fusariosis, mucormycosis and rare moulds.
Basilea Pharmaceutica overview
Basilea Pharmaceutica (Basilea) is a biopharmaceutical company. It develops and markets antibiotics, antifungals and oncology drugs. The company’s pipeline products include fosmanogepix, which treats candidemia and invasive candidiasis; Isavuconazole for invasive aspergillosis and mucormycosis; BAL2062, which targets invasive aspergillosis; ceftobiprole, which treats bacterial pneumonia; tonabacase for several staphylococcal infections. It markets its products under Cresemba and Zevtera. The company also operates in Russia, the US, China, Germany, Switzerland and Canada. Basilea is headquartered in Basel, Zurich, Switzerland.
For a complete picture of Fosmanogepix’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
